Acetylcholinesterase inhibitor with anticholinergic agent

This page covers all Acetylcholinesterase inhibitor with anticholinergic agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate), Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrrolate), Acetylcholinesterase; muscarinic acetylcholine receptors.

Targets

Acetylcholinesterase (neostigmine); Muscarinic acetylcholine receptors (glycopyrrolate) · Acetylcholinesterase (neostigmine); muscarinic acetylcholine receptors (glycopyrrolate) · Acetylcholinesterase; muscarinic acetylcholine receptors

Marketed (3)

• Neostigmine + Glycopyrrolate · Merck Sharp & Dohme LLC · Neuromuscular
  Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to prevent cholinergic side effects.
• Neostigmine w/ Glycopyrrolate · University of Texas Southwestern Medical Center · Neurology
  Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects.
• Neostigmine with glycopyrrolate · The Cleveland Clinic · Neurology
  Neostigmine inhibits acetylcholinesterase to increase acetylcholine levels, while glycopyrrolate blocks muscarinic receptors to counteract cholinergic side effects.